These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24602808)

  • 1. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
    Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
    Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.
    Iijima M; Yoshimizu T; Shimazaki T; Tokugawa K; Fukumoto K; Kurosu S; Kuwada T; Sekiguchi Y; Chaki S
    Br J Pharmacol; 2014 Jul; 171(14):3511-25. PubMed ID: 24654684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.
    Hodgson RA; Higgins GA; Guthrie DH; Lu SX; Pond AJ; Mullins DE; Guzzi MF; Parker EM; Varty GB
    Pharmacol Biochem Behav; 2007 Mar; 86(3):431-40. PubMed ID: 17291571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
    Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
    Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior.
    Bleickardt CJ; Mullins DE; Macsweeney CP; Werner BJ; Pond AJ; Guzzi MF; Martin FD; Varty GB; Hodgson RA
    Psychopharmacology (Berl); 2009 Mar; 202(4):711-8. PubMed ID: 18923820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models.
    Gupta D; Radhakrishnan M; Thangaraj D; Kurhe Y
    Eur J Pharmacol; 2014 Jul; 735():59-67. PubMed ID: 24747753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.
    Griebel G; Stemmelin J; Gal CS; Soubrié P
    Curr Pharm Des; 2005; 11(12):1549-59. PubMed ID: 15892661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.
    Stemmelin J; Lukovic L; Salome N; Griebel G
    Neuropsychopharmacology; 2005 Jan; 30(1):35-42. PubMed ID: 15367924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
    Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
    Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Vasopressin V1b Receptor Blockade on Activity of the Hypothalamic-Pituitary-Adrenal Axis in Old Monkeys with Depression-Like and Anxious Behavior Subjected to Stress or Injected with Vasopressin.
    Goncharova ND; Chigarova OA; Oganyan TE
    Bull Exp Biol Med; 2018 Nov; 166(1):86-91. PubMed ID: 30450521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin V1B Receptor Antagonists as Potential Antidepressants.
    Chaki S
    Int J Neuropsychopharmacol; 2021 Jul; 24(6):450-463. PubMed ID: 33733667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
    Wesołowska A; Nikiforuk A
    Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression.
    Kassai F; Schlumberger C; Kedves R; Pietraszek M; Jatzke C; Lendvai B; Gyertyán I; Danysz W
    Behav Pharmacol; 2012 Aug; 23(4):397-406. PubMed ID: 22785385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice.
    Thoeringer CK; Erhardt A; Sillaber I; Mueller MB; Ohl F; Holsboer F; Keck ME
    J Psychopharmacol; 2010 May; 24(5):733-43. PubMed ID: 19346277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin in health and disease with a focus on affective disorders.
    Zelena D
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):286-303. PubMed ID: 22954353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant-like and anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa).
    Zhang LM; Zhao N; Guo WZ; Jin ZL; Qiu ZK; Chen HX; Xue R; Zhang YZ; Yang RF; Li YF
    Neuropharmacology; 2014 Jun; 81():116-25. PubMed ID: 24067925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.
    Chaki S; Hirota S; Funakoshi T; Suzuki Y; Suetake S; Okubo T; Ishii T; Nakazato A; Okuyama S
    J Pharmacol Exp Ther; 2003 Feb; 304(2):818-26. PubMed ID: 12538838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.
    Overstreet DH; Griebel G
    Pharmacol Biochem Behav; 2005 Sep; 82(1):223-7. PubMed ID: 16181667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action.
    Andreasen JT; Fitzpatrick CM; Larsen M; Skovgaard L; Nielsen SD; Clausen RP; Troelsen K; Pickering DS
    Brain Res; 2015 Mar; 1601():117-26. PubMed ID: 25578259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The vasopressin V1b receptor as a therapeutic target in stress-related disorders.
    Griebel G; Simiand J; Stemmelin J; Gal CS; Steinberg R
    Curr Drug Targets CNS Neurol Disord; 2003 Jun; 2(3):191-200. PubMed ID: 12769799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.